ReviewDigestive diseases and sciences2026
NHE1 in Gastrointestinal Inflammation and Cancer: A Double-Edged Regulator.
Review in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ALG10 as a Novel Pro-fibrotic Mediator in IBD: Promise and Mechanistic Questions.Digestive diseases and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeNa
methodsA narrative review of the current literature was conducted, focusing on three major aspects of NHE1 biology: molecular regulation and basic cellular functions, inflammatory and fibrotic remodeling, and digestive cancer biology.
resultsUnder physiological conditions or during acute injury, NHE1-mediated pH regulation helps epithelial cells adapt to acid-base stress, maintain barrier integrity, and support mucosal repair. In chronic disease, however, sustained or dysregulated NHE1 activity may contribute to persistent inflammation, stromal remodeling, and pathological tissue repair. In digestive cancers, NHE1 has mainly been studied for its role in tumor pH regulation. By promoting intracellular alkalinization and extracellular acidification, NHE1 can favor tumor cell survival, migration, invasion, extracellular matrix interactions, and resistance to anticancer treatment. However, its role is not uniformly tumor-promoting. In some digestive tumors, reduced NHE1 expression or activity is associated with more aggressive disease, suggesting that NHE1 may also contribute to epithelial homeostasis, differentiation, or growth control under specific conditions.
conclusionTaken together, the effects of NHE1 in digestive diseases are highly context dependent. Appropriate NHE1-mediated pH regulation can support epithelial adaptation and tissue repair, whereas sustained or dysregulated activity may promote chronic inflammation, fibrosis, and tumor progression. The observation that reduced NHE1 activity may also be unfavorable in certain tumors further highlights the importance of disease context, cell type, and microenvironment. A better understanding of these context-dependent effects may help guide the development of more selective NHE1-based biomarkers and therapeutic strategies.
Indexed as
Identifiers
42635895What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.